
|Articles|November 15, 2013
- NSCLC (Issue 1)
- Volume 1
- Issue 1
Molecular Targeted Agents for Stage III NSCLC
Author(s)Bilal Piperdi, MD
Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, comments on molecular targeted agents for stage III non-small cell lung cancer (NSCLC).
Advertisement
Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, comments on molecular targeted agents for stage III non-small cell lung cancer (NSCLC).
Read more aboutmolecular targets in NSCLC
Articles in this issue
about 12 years ago
Molecular Targets in Non-Small Cell Lung Cancerabout 12 years ago
Multidisciplinary Perspectives: Molecular Testing in NSCLCabout 12 years ago
World Conference on Lung Cancer 2013 Highlightsabout 12 years ago
Guidelines for Molecular Testing in Lung Cancerabout 12 years ago
The Treatment of Lung Cancer Subgroupsabout 12 years ago
Treating Squamous vs Nonsquamous DiseaseAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5






































